B of A Securities Reiterates Buy Rating on Merck & Co.
B of A Securities maintains its buy rating on Merck with a $141 price target, a 9.73% upside from the current price.
Key Points
- B of A Securities reiterated its buy rating on Merck & Co., Inc. (NYSE: MRK) with a price target of $141 on June 30, 2026.
- B of A Securities's $141 price target implies 9.73% upside from Merck & Co., Inc.'s ($MRK) current $128.50 share price.
- Merck's stock traded near $129.38 on Tuesday, with a market cap of $317.8 billion and a P/E ratio of 36.24.
- Insiders including Kathy Warden and Paul Rothman bought shares on May 29, 2026, while analysts like Scotiabank also maintained buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
B of A Securities reiterated its buy rating on Merck & Co., Inc. (NYSE: MRK) with a price target of $141. This update from analyst Tim Anderson was issued on June 30, 2026. Merck's stock traded near $129.38 on Tuesday.
B of A Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Merck & Co., Inc. Stock Down 13.4%
Shares of NYSE:MRK traded around $129.38 on Tuesday. Merck & Co., Inc. has a market capitalization of approximately $317.8 billion. The stock features a P/E ratio of 36.24 and a forward P/E of 13.46, indicating different expectations for future earnings. Its beta of 0.218 suggests relatively low volatility compared to the broader market. The stock has seen a 52-week low of $76.66 and a high of $128.78, with moving averages of $115.84 over 50 days and $106.33 over 200 days.
$MRK price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Merck reported revenue of $65.77 billion, showing a modest growth of 4.9%. The company achieved an earnings per share (EPS) of 3.55. Its net margin stands at 13.6%, and return on equity (ROE) is 18.9%. Merck plans to announce its next earnings on August 4, 2026.
Dividend
Merck offers an annual dividend rate of $3.40, which translates to a yield of 2.64%. The dividend payout ratio is quite high at 93.52%, indicating the portion of earnings distributed as dividends.
Insider Buying and Selling at Merck & Co., Inc.
On May 29, 2026, several insiders, including Kathy Warden and Paul Rothman, purchased 1,853 shares each at an average price of $118.72. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 30, 2026, B of A Securities maintained its buy rating on Merck with a price target of $141. On the same day, Scotiabank also kept its buy rating but with a higher target of $155. Earlier, on June 24, 2026, CICC initiated coverage with a buy rating and a $138 target. The consensus among 28 analysts is a buy recommendation, with a mean price target of $130.39.
About Merck & Co., Inc.
Merck & Co., Inc., headquartered in Rahway, New Jersey, operates as a global healthcare company. It provides pharmaceuticals for human health and veterinary products. The company is known for its brands like Keytruda, Gardasil, and Januvia. Merck collaborates with other firms like Daiichi Sankyo and AstraZeneca to develop new treatments. Led by CEO Robert M. Davis, the company employs about 73,000 people worldwide.
Bottom Line
Merck & Co., Inc. continues to be a significant player in the healthcare sector, with strong institutional support and favorable analyst ratings. The reiterated buy rating by B of A Securities reflects continued confidence in the company's outlook. As always, investors should remember that these ratings are based on past data and projections, which could change.
Get Merck & Co., Inc. alerts
New 13F filings, insider trades, and analyst moves on $MRK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.